Anti-vegf treatment in neovascular age-related macular degeneration: A treat-and-extend protocol over 2 years

Retina

Volumn 34, Issue 8, 2014, Pages 1531-1538

  Abedi, Farshad ^a   Wickremasinghe, Sanjeewa ^a   Islam, Amirul F M ^a   Inglis, Kellie M ^a   Guymer, Robyn H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Age related macular degeneration; Bevacizumab; Neovascular; Ranibizumab; Treat and extend

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; EARLY TREATMENT DIABETIC RETINOPATHY STUDY SCORE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; SCORING SYSTEM; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84905108373     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000134     Document Type: Article

References (17)

1. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
2. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
4. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118: 831-839.
5. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
6. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411.
7. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-248.
8. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-671.
9. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
10. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009; 148: 43-58.
11. Spaide R. Ranibizumab according to need: a treatment for agerelated macular degeneration. Am J Ophthalmol 2007; 143: 679-680.
12. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011; 31: 26-30.
13. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010; 117: 2134-2140.
14. Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treatand- extend regimen: clinical and economic impact. Am J Ophthalmol 2012; 153: 468-473.
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
16. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 246-252.
17. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144: 850-857.